Biomarin Pharmaceutical Inc (BMRN) concluded trading on Thursday at a closing price of $58.55, with 3.98 million shares of worth about $233.18 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -8.89% during that period and on May 29, 2025 the price saw a gain of about 0.79%. Currently the company’s common shares owned by public are about 191.76M shares, out of which, 189.06M shares are available for trading.
Stock saw a price change of 0.12% in past 5 days and over the past one month there was a price change of -7.47%. Year-to-date (YTD), BMRN shares are showing a performance of -10.92% which decreased to -22.47% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $52.93 but also hit the highest price of $94.85 during that period. The average intraday trading volume for Biomarin Pharmaceutical Inc shares is 1.85 million. The stock is currently trading -1.59% below its 20-day simple moving average (SMA20), while that difference is down -6.21% for SMA50 and it goes to -14.57% lower than SMA200.
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) currently have 191.76M outstanding shares and institutions hold larger chunk of about 98.21% of that.
The stock has a current market capitalization of $11.23B and its 3Y-monthly beta is at 0.19. PE ratio of stock for trailing 12 months is 21.73, while it has posted earnings per share of $2.69 in the same period. Its PEG reads 0.65 and has Quick Ratio of 3.49 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BMRN, volatility over the week remained 0.81% while standing at 1.78% over the month.
Stock’s fiscal year EPS is expected to rise by 57.82% while it is estimated to increase by 19.85% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on February 24, 2025 offering an Outperform rating for the stock and assigned a target price of $98 to it. Coverage by Wolfe Research stated Biomarin Pharmaceutical Inc (BMRN) stock as an Outperform in their note to investors on November 15, 2024, suggesting a price target of $95 for the stock. On October 30, 2024, William Blair Downgrade their recommendations, while on October 10, 2024, Raymond James Resumed their ratings for the stock with a price target of $79. Stock get an Outperform rating from Bernstein on August 20, 2024.
